按此前披露，强生公司预计该交易将使2024年调整后每股收益稀释约0.24美元，2025年稀释约0.06美元。Johnson & Johnson (JNJ.US) has completed the acquisition of private medical device company V-Wave Ltd. Approximately $0.6 billion in research and development expenses (IPR&D) will be generated in the fourth quarter of 2024.
The Zhitong Finance App learned that Johnson & Johnson (JNJ.US) has completed the acquisition of private medical equipment company V-Wave Ltd. In August of this year, the pharmaceutical giant agreed to buy V-wave with an upfront payment of $0.6 billion. The deal will be viewed as an asset acquisition and will generate approximately $0.6 billion in research and development expenses (IPR&D) in the fourth quarter of 2024.
As previously announced, V-Wave, which focuses on cardiovascular disease treatment programs, will operate as part of Johnson & Johnson Healthcare Technology.
According to previous disclosures, Johnson & Johnson expects the transaction to dilute adjusted earnings per share by approximately $0.24 in 2024 and by about $0.06 in 2025.
